Telisotuzumab-EMRELIS price in foreign markets and channels for purchasing imported drugs

Telisotuzumab (EMRELIS) is not currently on the market in China, so domestic patients cannot directly purchase and use it through formal channels. The drug is mainly used to treat advanced non-small cell lung cancer (NSCLC) with high expression of c-Met. It is an antibody-coupled targeted drug (ADC) that can selectively identify and kill tumor cells, providing a new treatment option for patients with refractory lung cancer.

In overseas markets, the price of EMRELIS is relatively high. The official retail price shows that each box is about 45,000 yuan. The specific price may fluctuate due to exchange rates, regional and hospital discounts. There are currently no generic versions, and imported drugs are expensive and must be purchased through formal channels to ensure drug quality and efficacy.

Since it is not yet on the market in China, patients who want to use EMRELIS usually need to obtain it through special channels. For example, participate in overseas or international clinical trials, or apply for a special drug license through a medical institution qualified to import drugs. In addition, there are also patients who purchase through overseas hospital prescriptions and pharmacies, but they need to pay attention to logistics, cold chain and regulatory compliance issues.

In general, terituzumab provides a breakthrough treatment option for patients with c-Methigh expression of NSCLC. Before patients obtain drugs, doctors should evaluate the indications and tumor c-Met expression levels, understand potential adverse reactions and follow-up monitoring arrangements, and fully consider high costs and safety issues. After it is launched in China and included in medical insurance in the future, it will be possible to provide more patients with accessible and standardized treatment pathways.

Reference materials:https://www.drugs.com/